

1647
JFW

Please Direct All Correspondence to Customer Number **30,313**

TRANSMITTAL LETTER

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT


Applicant : Goddard, et al.
App. No : 10/063,599
Filed : May 3, 2002
For : SECRETED AND TRANSMEMBRANE
POLYPEPTIDES AND NUCLEIC ACIDS
ENCODING THE SAME
Examiner : Sandra L. Wegert
Art Unit : 1647

CERTIFICATE OF MAILING

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

July 13, 2005

(Date)



AnneMarie Kaiser, Reg. No. 37,649

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


Dear Sir:

Enclosed for filing in the above-identified application are:

- (X) A Supplemental Information Disclosure Statement and PTO/SB/08 equivalent listing references for consideration:
 - (X) Listing and enclosing 5 references.
- (X) The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 11-1410.
- (X) Return prepaid postcard.


AnneMarie Kaiser
Registration No. 37,649
Attorney of Record
Customer No. 30,313
(619) 235-8550





SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT


Applicant : Goddard, et al.
App. No : 10/063,599
Filed : May 3, 2002
For : SECRETED AND
TRANSMEMBRANE POLYPEPTIDES
AND NUCLEIC ACIDS ENCODING
THE SAME
Examiner : Sandra L. Wegert
Art Unit : 1647

CERTIFICATE OF MAILING

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

July 13, 2005

(Date)


AnneMarie Kaiser, Reg. No. 37,649

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application is a Supplemental Information Disclosure Statement by Applicant (PTO/SB/08 equivalent), listing 5 foreign patent references and/or non-patent literature to be considered by the Examiner.

This Supplemental Information Disclosure Statement is being filed within three months of the filing date, with an RCE or before receipt of a first office action after an RCE and no fee is required.

The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 11-1410.


Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated:

July 13, 2005

By:



AnneMarie Kaiser
Registration No. 37,649
Attorney of Record
Customer No. 30,313
(619) 235-8550

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Multiple sheets used when necessary)

SHEET 1 OF 1

Application No.	10/063,599
Filing Date	May 3, 2002
First Named Inventor	Goddard, et al.
Art Unit	1647
Examiner	Sandra L. Wegert
Attorney Docket No.	GNE.3230R1C72

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
	1	FESSLER, M., et al. 2002. A Genomic and Proteomic Analysis of Activation of the Human Neutrophil by Lipopolysaccharide and Its Medication by p38 Mitogen-activated Protein Kinase. <i>The Journal of Biological Chemistry</i> , pp. 31291-31302.	
	2	HANASH, S. 2003. Making sense of microarray data to classify cancer. <i>The Pharmacogenomics Journal</i> , 3:308-311.	
	3	HANASH, S. March 2005. Integrated global profiling of cancer. <i>Nature Reviews, Applied Proteomics Collection</i> , pp. 9-14.	
	4	HANCOCK, W. S. 2004. Do we have enough biomarkers? <i>Journal of Proteome Research</i> , 3(4):685.	
	5	WANG, et al. 1996. mRNA Differential display: Application in the discovery of novel pharmacological targets. <i>Trends Pharmacol. Sci.</i> , 17(8):276-279.	

1812926
071305

Examiner Signature	Date Considered
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

T¹ - Place a check mark in this area when an English language Translation is attached.